We Accelerate Discovery

You are here


Science News

This page was last updated Fall 2014

  • Cleave Biosciences Initiates Phase 1 Clinical Trial of CB-5083 in Patients with Multiple Myeloma Exit Disclaimer
    September 4, 2014
    A compound originally identified with the support of the Molecular Libraries program has led to a drug candidate now entering a Phase 1 clinical trial in patients with multiple myeloma that has proved resistant to two or more established treatment options.

  • The GHIT fund shows its cards Exit Disclaimer
    November 29, 2013
    ML probe #341, a compound developed by the NIH Molecular Libraries Probe Production Center at the Broad Institute of MIT and Harvard University, part of the NIH Common Fund Molecular Libraries Program, was chosen for further development by The Global Health Innovative Technology (GHIT) fund as a candidate therapeutic for Chagas disease.

  • Therapeutic candidate targeting S1P1 advances in clinical trials for Multiple Sclerosis. For more about Receptos Inc., click here Exit disclaimer
    December 2013
    Receptos, Inc. announced in December, 2013 that they completed an analysis of the Phase 2 portion of its Phase 2/3 trial of RPC1063 in relapsing multiple sclerosis (RMS).

  • Scripps research team discovers treatable mechanism responsible for often deadly response to flu    Exit Disclaimer
    September 15, 2011
    Researchers at The Scripps Research Institute have found a novel mechanism by which certain viruses such as influenza trigger a type of immune reaction that can severely sicken or kill those infected.
  • Finding a Perfect Match – Matchmaking by the Molecular Libraries Program  
    March 7, 2011
    A continent apart, synthetic chemist Dr. Gregory Fu, of MIT, Cambridge, MA and Dr. Ben Cravatt of Scripps, La Jolla, CA formed a productive scientific collaboration after a unique series of chemicals Dr. Fu donated to a public repository was found to inhibit a protein of interest to Dr. Cravatt.
  • Scripps Research and MIT scientists discover class of potent anti-cancer compounds Exit Disclaimer
    March 7, 2011
    Working as part of a public program to screen compounds to find potential medicines and other biologically useful molecules, scientists from The Scripps Research Institute and Massachusetts Institute of Technology (MIT) have discovered an extremely potent class of potential anti-cancer and anti-neurodegenerative disorder compounds.
  • Going Underground in Search of New Drugs  Exit Disclaimer
    February 1, 2011
    Every few months, chemist Brian Bachmann sheds his white lab coat, collects his flashlight, helmet, surgical gloves and knotted rope, puts on old clothes and hiking boots and heads to a nearby cave.
  • From The Lab To The Clinic: Discovery From Molecular Libraries Program Enters Clinical Trials
    January 27, 2011
    Researchers in the Common Fund’s Molecular Libraries and Imaging program are tackling a tough biological problem—finding potential drug candidates that target G protein-coupled receptors (GPCRs).
  • Scripps Research and Vanderbilt Launch Joint Institute to Advance Science at Interface of Chemistry and Medicine Exit Disclaimer
    January 13, 2011
    The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.
  • Innovative Approaches to Study Complex Signaling Pathways in Cells
    Researchers at John Hopkins University, led by Dr. Toru Komatsu and supported through the Common Fund’s Molecular Libraries and Imaging program, have developed a novel system to target and perturb specific molecular activities and communications pathways within cells. The technique may help elucidate the structure and function of complex signaling networks that perform basic functions within cells and may someday be targeted in disease therapies. The work was published in the journal Nature Methods (2010, 7(3):206-208).
  • Vanderbilt University Partners with Massachusetts Firm on Drug Discovery Research Exit Disclaimer
    January 6, 2010
    Vanderbilt University Medical Center has entered into a collaborative research agreement with Seaside Therapeutics LLC to discover and develop potential drugs to treat developmental disorders such as Fragile X syndrome and autism.
Up to Top